Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.

dc.contributor.author

Hashmi, Nazish K

dc.contributor.author

Ghadimi, Kamrouz

dc.contributor.author

Srinivasan, Amudan J

dc.contributor.author

Li, Yi-Ju

dc.contributor.author

Raiff, Robert D

dc.contributor.author

Gaca, Jeffrey G

dc.contributor.author

Root, Adam G

dc.contributor.author

Barac, Yaron D

dc.contributor.author

Ortel, Thomas L

dc.contributor.author

Levy, Jerrold H

dc.contributor.author

Welsby, Ian J

dc.date.accessioned

2024-01-10T18:26:23Z

dc.date.available

2024-01-10T18:26:23Z

dc.date.issued

2019-05

dc.description.abstract

BACKGROUND/OBJECTIVES:Prothrombin complex concentrates (PCC) are increasingly administered off-label in the United States to treat bleeding in cardiovascular surgical patients and carry the potential risk for acquired thromboembolic side-effects after surgery. Therefore, we hypothesized that the use of low-dose 3-factor (3F) PCC (20-30 IU/kg), as part of a transfusion algorithm, reduces bleeding without increasing postoperative thrombotic/thromboembolic complications. MATERIALS/METHODS:After IRB approval, we retrospectively analysed 114 consecutive, complex cardiovascular surgical patients (age > 18 years), between February 2014 and June 2015, that received low-dose 3F-PCC (Profilnine® ), of which seven patients met established exclusion criteria. PCC was dosed according to an institutional perioperative algorithm. Allogeneic transfusions were recorded before and after PCC administration (n = 107). The incidence of postoperative thromboembolic events was determined within 30 days of surgery, and Factor II levels were measured in a subset of patients (n = 20) as a quality control measure to avoid excessive PCC dosing. RESULTS:Total allogeneic blood product transfusion reached a mean of 12·4 ± 9·9 units before PCC and 5·0 ± 6·3 units after PCC administration (P < 0·001). The mean PCC dose was 15·8 ± 7·1 IU/kg. Four patients (3·8%) each experienced an ischaemic stroke on postoperative day 1, 2, 4 and 27. Seven patients (6·5%) had acquired venous thromboembolic disease within 10 days of surgery. Median factor II level after transfusion algorithm adherence and PCC administration was 87%. CONCLUSIONS:3F-PCC use for refractory bleeding after cardiovascular surgery resulted in reduced transfusion of allogeneic blood and blood products. Adherence to this algorithmic approach was associated with an acceptable incidence of postoperative thrombotic/thromboembolic complications.

dc.identifier.issn

0042-9007

dc.identifier.issn

1423-0410

dc.identifier.uri

https://hdl.handle.net/10161/29728

dc.language

eng

dc.publisher

Wiley

dc.relation.ispartof

Vox sanguinis

dc.relation.isversionof

10.1111/vox.12774

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.subject

Blood Platelets

dc.subject

Humans

dc.subject

Thromboembolism

dc.subject

Hemorrhage

dc.subject

Fibrinogen

dc.subject

Blood Coagulation Factors

dc.subject

Blood Coagulation Tests

dc.subject

Blood Transfusion

dc.subject

Cardiopulmonary Bypass

dc.subject

Postoperative Period

dc.subject

Retrospective Studies

dc.subject

Hemostasis

dc.subject

Blood Coagulation

dc.subject

Algorithms

dc.subject

Adolescent

dc.subject

Adult

dc.subject

Aged

dc.subject

Aged, 80 and over

dc.subject

Middle Aged

dc.subject

United States

dc.subject

Female

dc.subject

Male

dc.subject

Young Adult

dc.title

Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.

dc.type

Journal article

duke.contributor.orcid

Hashmi, Nazish K|0000-0001-9738-3754

duke.contributor.orcid

Ghadimi, Kamrouz|0000-0002-9287-7541

duke.contributor.orcid

Li, Yi-Ju|0000-0001-6996-4834

duke.contributor.orcid

Levy, Jerrold H|0000-0003-3766-4962

duke.contributor.orcid

Welsby, Ian J|0000-0002-2789-5612

pubs.begin-page

374

pubs.end-page

385

pubs.issue

4

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Anesthesiology

pubs.organisational-group

Anesthesiology, Cardiothoracic

pubs.organisational-group

Medicine

pubs.organisational-group

Pathology

pubs.organisational-group

Surgery

pubs.organisational-group

Medicine, Hematology

pubs.organisational-group

Surgery, Cardiovascular and Thoracic Surgery

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Molecular Physiology Institute

pubs.organisational-group

Biostatistics & Bioinformatics, Division of Integrative Genomics

pubs.publication-status

Published

pubs.volume

114

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PCC Vox Sang 2019.pdf
Size:
495.39 KB
Format:
Adobe Portable Document Format